

August 14, 2024

To,  
The Manager  
Listing Department,  
**The National Stock Exchange of India Limited**  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400051

Dear Sir/ Madam,

**Trading Symbol: ZOTA**

**Sub: Outcome of Board Meeting held on Wednesday, August 14, 2024**

**Ref.: Regulation 30 & 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

With reference to the captioned subject, we would like to inform you that the Board of Directors of Zota Health Care Limited (the “Company”) in its Meeting held on Wednesday, August 14, 2024 at 02:00 P.M. at the Zota House, Bhagwan Aiyappa Complex, Next to Batliboi, Udhna-Navsari State Highway, Surat – 394210, Gujarat, have, *inter alia*, discussed and approved following businesses:

1. Considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2024 along with Limited Review Reports thereon. Financial Results and Limited Review Reports are enclosed herewith (**Annexure – I**).

Unaudited standalone and consolidated financial results for the period as aforementioned shall be available on the website of the Stock Exchange where the shares of the Company are listed i.e at [www.nseindia.com](http://www.nseindia.com) and on Company’s website at [www.zotahealthcare.com](http://www.zotahealthcare.com)

2. Pursuant to the receipt of the application money i.e. Rs 509/- per equity shares, allotment of 8,73,294 (Eight Lakhs Seventy Three Thousand Two Hundred Ninety Four Only) Equity Shares of face value of Rs. 10.00/- each at an issue price of Rs. 509/- (Rupees Five Hundred And Nine Only) per equity shares (including a premium of Rs. 499/- (Rupees Four Hundred And Ninety Nine Only)) aggregating to Rs. 44,45,06,646/- (Rupees Forty Four Crores Forty Five Lakhs Six Thousand Six Hundred Forty Six Only) by way of a preferential allotment to the Promoter Group And Non Promoter Group Category.

Equity shares allotted on the preferential basis shall rank pari passu with the existing equity shares of the Company in all respects.

The requisite disclosure, pursuant to Para A of Part A of Schedule III of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015 read with SEBI Circular No CIR/CFD/CMD/4/2015 dated September 9, 2015, is enclosed as (**Annexure- II**).

**Registered Office:**

Zota House, 2/896, Hira Modi Street,  
Sagrampura, Surat-395002 Ph: +91 261 2331601  
Email: [info@zotahealthcare.com](mailto:info@zotahealthcare.com)  
Web: [www.zotahealthcare.com](http://www.zotahealthcare.com)

CIN: L24231GJ2000PLC038352

3. Pursuant to the receipt of the application money being 25% of the warrant issue price i.e. Rs 127.25/- per fully convertible warrants aggregating to Rs. 33,65,55,381/- (Rupees Thirty Three Crores Sixty Five Lakhs Fifty Five Thousand Three Hundred And Eighty One Only), allotment of 26,44,836 (Twenty Six Lakhs Forty Four Thousand Eight Hundred Thirty Six Only) fully Convertible Warrants ("Warrants") each convertible into, or exchangeable, at an option of Warrant Holder(s), within a maximum period of 18 (eighteen) months from the date of allotment of warrants into equivalent number of fully paid up equity share of the Company of face value of Rs.10/- (Rupees Ten) each, at an issue price of Rs. 509/- (Rupees Five Hundred And Nine Only, (including the warrant subscription price and the warrant exercise price)) each aggregating to an amount of up to Rs. 1,34,62,21,524/- (Rupees One Hundred Thirty Four Crores Sixty Two Lakhs Twenty One Thousand Five Hundred Twenty Four Only) by way of a preferential allotment to the Promoter Group And Non Promoter Group Category.

Equity shares to be allotted on exercise of warrants on the preferential basis shall rank pari passu with the existing equity shares of the Company in all respects.

The requisite disclosure, pursuant to Para A of Part A of Schedule III of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015 read with SEBI Circular No CIR/CFD/CMD/4/2015 dated September 9, 2015, is enclosed as **(Annexure- III)**.

The Board meeting concluded at 18:50 P.M.

This is for your information and record.

Thanking you,

Yours faithfully,

For **Zota Health Care Limited**

**Ashvin Variya**  
**(Company Secretary & Compliance Officer)**

**SHIVANGI PAREKH & CO.****CHARTERED ACCOUNTANTS**

---

Independent Auditor's Review Report on Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,

**The Board of Directors of  
Zota Health Care Limited**

We have reviewed the accompanying statement of Standalone Unaudited Financial Results of **Zota Health Care Limited** (the "Company") for the quarter ended **June 30, 2024** ("the Statement") attached herewith, being submitted by the Company pursuant to requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time (the "Regulations").

**Management's Responsibility**

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

**Auditor's Responsibility**

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

**Conclusion**

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian accounting standards and other recognized accounting practices and policies has not disclosed the



---

302, SAI BHAVAN, NR. NEW SAIBABA TEMPLE, OPP. SMC MULTILEVEL PARKING, SHAHPORE,

SURAT-395002.

# SHIVANGI PAREKH & CO.

CHARTERED ACCOUNTANTS

---

information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Date: 14-08-2024

Place: Surat



For Shivangi Parekh & Co.  
Chartered Accountants

ICAI FRN: 131449W

*Shivangi*  
CA. Shivangi Mehta

Proprietor

M. No.118936

UDIN: 24118936BKEXKR5289

---

302, SAI BHAVAN, NR. NEW SAIBABA TEMPLE, OPP. SMC MULTILEVEL PARKING, SHAHPORE,

SURAT-395002.

Particulars	Quarter Ended			Year Ended
	30-06-2024 (Unaudited)	31-03-2024 (Audited)	30-06-2023 (Unaudited)	31-03-2024 (Audited)
I. Revenue from Operations	5220.36	4734.96	3525.07	16658.50
II. Other Income	46.88	69.38	35.55	205.19
III. <b>Total Income</b>	<b>5267.25</b>	<b>4804.33</b>	<b>3560.62</b>	<b>16863.69</b>
IV. <b>Expenses:</b>				
Cost of Materials Consumed	279.11	293.75	262.69	1277.46
Purchases of Stock-in-Trade	2344.68	3565.39	1988.19	9520.35
Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	560.23	(1054.65)	124.12	(352.67)
Employee Benefit Expenses	644.17	613.12	377.55	1997.36
Finance Costs	41.92	6.42	4.67	36.47
Depreciation / Amortisation and Depletion Expense	67.64	85.86	55.08	300.73
Other Expenses	1097.29	1278.83	710.99	3593.37
<b>Total Expenses</b>	<b>5035.03</b>	<b>4788.71</b>	<b>3523.28</b>	<b>16373.07</b>
V. Profit before Exceptional items and tax from continuing operations (III-IV)	232.21	15.62	37.34	490.61
VI. Exceptional Items	-	-	-	-
VII. Profit/(loss) before tax	232.21	15.62	37.34	490.61
VIII. Tax Expense:				
(1) Current tax	64.71	14.04	12.96	153.08
(1.1) I.T. & DD Tax Provision Created Short/ excess	-	-	-	(6.28)
(2) Deferred Tax	(9.07)	20.74	(3.17)	(5.82)
IX. Profit/ (Loss) for the period from Continuing Operations (VII-VIII)	158.43	22.33	21.22	337.99
X. Profit/(loss) before tax from discontinued operations	-	-	-	-
XI. Tax Expense of discontinued Operations	-	-	-	-
XII. Profit/ (Loss) from Discontinued Operations (after Tax) (X- XI)	-	-	-	-
XIII. <b>Profit/ (Loss) for the period</b>	<b>158.43</b>	<b>22.33</b>	<b>21.22</b>	<b>337.99</b>
XIV. <b>Other Comprehensive Income</b>				
A (i) Items that will not be reclassified to Statement of profit and loss	10.62	3.88	(20.35)	19.82
(ii) Income Tax relating to items that will not be reclassified to Statement of profit and loss	(2.67)	(0.98)	5.12	(4.99)
B (i) Items that will be reclassified to Statement of profit and loss	-	-	-	-
(ii) Income Tax relating to items that will be reclassified to profit and loss	-	-	-	-
Other comprehensive income for the period, net of tax	7.94	2.90	(15.22)	14.83
<b>Total comprehensive income for the period (XIII + XIV)</b>	<b>166.37</b>	<b>25.23</b>	<b>5.99</b>	<b>352.82</b>
Paid-up Equity Share Capital	2653.43	2584.73	2516.03	2584.73
Other Equity				9592.80
Earnings per equity share of face value of ₹ 10 each				
(1) Basic (in ₹)	0.60	0.09	0.08	1.32
(2) Diluted (in ₹)	0.60	0.08	0.08	1.29

\* denotes figures less than a lakh  
 For and on behalf of the Board

*H.M. Zota*  
 (Whole Time Director)  
 Himanshu M. Zota  
 (Din : 01097722)

*Ashvin Variya*  
 Company Secretary  
 Ashvin Variya

*Viral Mandviwala*  
 Chief Financial Officer  
 Viral Mandviwala

Date: 14-08-2024  
 Place : Surat



For Shivangi Parekh & Co.  
 Chartered Accountants  
 Firm No. 131449W

*Shivangi Mehta*  
 CA: Shivangi Mehta  
 Proprietor  
 M. No. 118936

### Corporate Office :

Zota House, 2/896, Hira Modi Street,  
 Sagrampura, Surat - 395 002 | Ph: +91 261 2331601  
 Email: info@zotahealthcare.com  
 Web : www.zotahealthcare.com

### Plant :

Plot no. 169, Surat Special Economic Zone,  
 Nr. Sachin Railway Station, Sachin,  
 Surat - 394 230 (Guj.) India  
 Ph: +91 261 2397122

# SHIVANGI PAREKH & CO.

CHARTERED ACCOUNTANTS

---

Independent Auditor's Review Report on Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,  
**The Board of Directors of  
Zota Health Care Limited**

We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Zota Health Care Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/(loss) after tax and total comprehensive income / loss for the quarter ended **June 30, 2024** ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended as amended from time to time (the "Regulation").

#### **Management's Responsibility**

This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

#### **Auditor's Responsibility**

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the results of the following entities:

- i. Zota Health Care Limited (Parent)
- ii. Zota Healthcare Lanka (Pvt) Ltd (Wholly Owned Subsidiary)
- iii. Davaindia Health Mart Limited (Wholly Owned Subsidiary)
- iv. Everyday Herbal Beauty Care Private Limited (Subsidiary)



---

302, SAI BHAVAN, NR. NEW SAIBABA TEMPLE, OPP. SMC MULTILEVEL PARKING, SHAHPORE,

SURAT-395002.

# SHIVANGI PAREKH & CO.

## CHARTERED ACCOUNTANTS

- 
- v. Everyday Herbal Beauty And Wellness Care Private Limited (Subsidiary)

### Conclusion

Based on our review conducted and procedures performed as stated in paragraph 3, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

### Other Matters

We did not review the interim financial statements of the subsidiaries included in the consolidated unaudited total revenues of Rs. 1981.50 Lakhs, total net profit/(loss) after tax of Rs. (1366.21) Lakhs and total comprehensive income of Rs. (1364.94) Lakhs, for the quarter ended June 30, 2024, as considered in the consolidated unaudited financial results. These interim financial statements have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, associates and joint ventures, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.


Our conclusion on the Statement is not modified in respect of the above matters.

Date: 14-08-2024

Place: Surat



For Shivangi Parekh & Co.  
Chartered Accountants  
ICAI FRN: 131449W

  
CA. Shivangi Mehta  
Proprietor  
M. No.118936

UDIN: 24118936BKEXKS5021

healthcare Ltd.		Quarter Ended			
		30-06-2024	31-03-2024	30-06-2023	Year Ended 31-03-2024
Particulars		(Unaudited)	(Audited)	(Unaudited)	(Audited)
I.	Revenue from Operations	5630.06	4963.56	3864.82	18048.85
II.	Other Income	1.79	45.68	15.19	115.61
III.	<b>Total Income</b>	<b>5631.85</b>	<b>5009.25</b>	<b>3880.01</b>	<b>18164.46</b>
IV.	<b>Expenses:</b>				
	Cost of Materials Consumed	279.11	293.75	262.69	1277.46
	Purchases of Stock-in-Trade	2321.63	3555.39	1988.19	9520.35
	Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	33.36	(1580.06)	117.77	(1127.79)
	Employee Benefit Expenses	1624.65	1211.38	459.61	3045.05
	Finance Costs	289.80	168.09	83.25	478.82
	Depreciation / Amortisation and Depletion Expense	802.35	679.87	340.79	2008.51
	Other Expenses	1497.20	1621.61	908.68	4578.35
	<b>Total Expenses</b>	<b>6848.09</b>	<b>5960.05</b>	<b>4160.98</b>	<b>19780.75</b>
V.	Profit before Exceptional items and tax from continuing operations (III-IV)	(1216.24)	(950.81)	(280.97)	(1616.29)
VI.	Exceptional Items	-	-	-	-
VII.	Profit/(loss) before tax	(1216.24)	(950.81)	(280.97)	(1616.29)
VIII.	Tax Expense:				
	(1) Current tax	64.71	14.04	12.96	153.08
	(1.1) I.T. & DD Tax Provision Created Short/ excess	-	-	-	(6.28)
	(2) Deferred Tax	8.57	273.08	10.15	328.31
IX.	Profit/ (Loss) for the period from Continuing Operations (VII-VIII)	(1272.39)	(691.77)	(283.78)	(1434.79)
X.	Profit/(loss) before tax from discontinued operations	-	-	-	-
XI.	Tax Expense of discontinued Operations	-	-	-	-
XII.	Profit/ (Loss) from Discontinued Operations (after Tax) (X- XI)	-	-	-	-
XIII.	<b>Profit/ (Loss) for the period</b>	<b>(1272.39)</b>	<b>(691.77)</b>	<b>(283.78)</b>	<b>(1434.79)</b>
XIV.	<b>Other Comprehensive Income</b>				
	A (i) Items that will not be reclassified to Statement of profit and loss	12.39	8.08	(20.25)	24.59
	(ii) Income Tax relating to items that will not be reclassified to Statement of profit and loss	(3.12)	(2.03)	5.10	(6.18)
	B (i) Items that will be reclassified to Statement of profit and loss	(0.06)	(0.04)	(0.05)	(0.07)
	(ii) Income Tax relating to items that will be reclassified to profit and loss	0.01	0.01	0.01	0.02
	Other comprehensive income for the period, net of tax	9.23	6.03	(15.19)	18.36
	<b>Total comprehensive income for the period (XIII + XIV)</b>	<b>(1263.16)</b>	<b>(685.74)</b>	<b>(298.97)</b>	<b>(1416.42)</b>
	Profit attributable to:				
	Owners of the parent	(1272.39)	(691.77)	(283.78)	(1434.79)
	Non-controlling interest	-	-	-	-
	Other comprehensive income attributable to:				
	Owners of the parent	9.23	6.03	(15.19)	18.36
	Non-controlling interest	-	-	-	-
	<b>Total Comprehensive Income attributable to:</b>				
	Owners of the parent	(1263.16)	(685.74)	(298.97)	(1416.42)
	Non-controlling interest	-	-	-	-
	Paid-up Equity Share Capital	2653.43	2584.73	2516.03	2584.73
	Other Equity	-	-	-	6412.92
	Earnings per equity share of face value of ₹ 10 each				
	(1) Basic (in ₹)	(4.80)	(2.68)	(1.13)	(5.59)
	(2) Diluted (in ₹)	(4.80)	(2.62)	(1.13)	(5.47)

\* denotes figures less than a lakh

For and on behalf of the Board



(Whole Time Director)  
Himanshu M. Zota  
(Din : 01097722)



Company Secretary  
Ashvin Variya  
Date: 14-08-2024  
Place : Surat



Chief Financial Officer  
Viral Mandviwala


 For Shivangi Parekh & Co.  
Chartered Accountants  
Firm No. 131449W



CA Shivangi Mehta  
Proprietor  
M. No. 118936

**Corporate Office :**

 Zota House, 2/896, Hira Modi Street,  
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601  
Email: info@zotahealthcare.com  
Web : www.zotahealthcare.com

**Plant :**

 Plot no. 169, Surat Special Economic Zone,  
Nr. Sachin Railway Station, Sachin,  
Surat - 394 230 (Guj.) India  
Ph: +91 261 2397122





Notes: **healthcare Ltd.**

1. The above financial results for the quarter ended June 30, 2024 have been reviewed and recommended by the Audit Committee and subsequently approved by the Board of Directors at their meeting held on August 14, 2024.
2. The financial results have been prepared in accordance with the Indian Account Standards ("Ind As") as prescribed under section 133 of the Companies Act, 2013 read with (Indian Accounting Standards) rules, 2015, as amended.
3. The Statutory Auditors have carried out Limited Review of the financial results for the quarter ended June 30, 2024.
4. The Company has evaluated its Operating segment in accordance with IND AS 108 and has concluded that it is engaged in a single operating segment.
5. The consolidated results include the result of following companies:
  - A) wholly owned subsidiaries:
    - i) Zota Healthcare Lanka (Pvt) Ltd
    - ii) Davaindia Health Mart Limited
    - iii) Zota Nex Tech Limited
  - B) Subsidiaries:
    - i) Everyday Herbal Beauty Care Private Limited
    - ii) Everyday Herbal Beauty And Wellness Care Private Limited
6. The figures for quarter ended March 31, 2024 are balancing figures between the audited figures of the financial year ended March 31, 2024 and the published figures of the year-to-date (nine months) ended December 31, 2023, which were subjected to limited review report.
7. In the consolidated financial results, the Company has adopted Ind As 116 'Leases' and applied the Standard to its leases. This has resulted in recognizing a Right-of-Use Asset of Rs. 9134.79 lakhs and a corresponding Lease Liability of Rs. 9902.16 lakhs as at June 30, 2024. The impact of this on the consolidated profit for the quarter ended June 30, 2024 is Rs. 182.61 lakhs.
8. On May 09, 2024, the Company has acquired 56% stake in Everyday Group by acquiring 37,03,640 equity shares of 'Everyday Herbal Beauty Care Private Limited' and 7,12,730 equity shares of 'Everyday Herbal Beauty And Wellness Care Private Limited' respectively.
9. During the quarter; upon receipt of balance 75% amount i.e. Rs. 227.25/- per warrant of the warrants issue price, the Board of Directors of the Company has on April 06, 2024 and May 07, 2024 allotted 6,79,500 and 7,500 equity shares upon conversion of warrants to 13 Warrant Holders and 1 Warrant Holder respectively.
10. During the quarter, on May 06, 2024, the company has granted 13,600 stock options under Zota Health Care - Employee Stock Option Plan 2022' ("ZHL ESOP 2022"). As on June, 30, 2024, the Company has on cumulative basis granted 26,400 stock options under Zota Health Care - Employee Stock Option Plan 2022. Further, the options granted are yet to be exercised.
11. The figures for the corresponding previous period have been regrouped/reclassified wherever necessary, to make them comparable.

**Corporate Office :**

Zota House, 2/896, Hira Modi Street,  
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601  
Email: info@zotahealthcare.com  
Web : www.zotahealthcare.com

**Plant :**

Plot no. 169, Surat Special Economic Zone,  
Nr. Sachin Railway Station, Sachin,  
Surat - 394 230 (Guj.) India  
Ph: +91 261 2397122



## Annexure- II

Disclosure pursuant to Para A of Part A of Schedule III of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 read with read with SEBI Circular No CIR/CFD/CMD/4/2015 dated September 9, 2015

Disclosure post allotment of Securities by way of preferential issue

Sr. No.	Particulars	Details			
1	Outcome of the subscription	Allotment of 8,73,294 equity shares for an aggregate consideration of Rs. 44,45,06,646/- .			
2	Issue Price / allotted price (in case of convertibles)	The equity shares are issued at a price of Rs. 509/- each.			
3	Number of investor(s)	57 (Fifty seven)			
		<b>SR. NO.</b>	<b>NAME OF ALLOTTEES</b>	<b>CATEGORY (PROMOTER / NON PROMOTER)</b>	<b>NO OF EQUITY SHARES IN THE COMPANY ALLOTTED</b>
		1	Parag Chandulal Mehta	Non Promoter	34,381
		2	Alka Rajesh Agrawal	Non Promoter	14,735
		3	Kedia Seema	Non Promoter	2,456
		4	Sadhna Devi Chandak	Non Promoter	2,456
		5	Umesh Surendra Kamath	Non Promoter	2,456
		6	Meghana Divyagnan Sarvaiya	Non Promoter	2,456
		7	Nirmal Kumar Deepchand Gangwal	Non Promoter	24,558
		8	Piyush Goyal	Non Promoter	12,500
		9	Sharda Agarwal	Non Promoter	7,367
		10	Nachiket V Deo	Non Promoter	1,228
		11	Neeraj Khubchandani	Non Promoter	1,228
		12	Kaushik Daga	Non Promoter	49,116
		13	Kalpita Agencies Private Limited	Non Promoter	14,735
		14	Gaurav Karnawat	Non Promoter	24,558
		15	Neelima Karnawat	Non Promoter	24,558
		16	Manan Keval Doshi	Non Promoter	9,823
		17	Ramesh S Damani	Non Promoter	25,000

		18	Gautam Pranalal Shah	Non Promoter	2,456
		19	Hem Chand Jain	Non Promoter	11,051
		20	Ramgopal Investment And Trading Company Private Limited	Non Promoter	24,558
		21	Vikas Vijaykumar Khemani	Non Promoter	24,558
		22	Sameer Manchanda	Non Promoter	25,000
		23	Vijay Jain	Non Promoter	2,456
		24	Karan Manoj Maheshwari	Non Promoter	4,912
		25	Astralit Investments Private Limited	Non Promoter	24,558
		26	Pravin Pannalal Shah HUF	Non Promoter	25,000
		27	Jitendra Rasiklal Sanghavi	Non Promoter	9,823
		28	Alok Saraf	Non Promoter	4,912
		29	Priyanka Shwetkumar Koradiya	Non Promoter	36,250
		30	Satya Pal Gulati	Non Promoter	4,912
		31	Pankaj Prasoon HUF	Non Promoter	9,823
		32	Arham Samkit Gandhi	Non Promoter	12,500
		33	Megh Samkit Gandhi	Non Promoter	12,500
		34	Prafull Rai	Non Promoter	9,823
		35	Ashok Ramkishan Sikchi	Non Promoter	9,823
		36	Gaurav Jain	Non Promoter	6,631
		37	Raghav Bahl	Non Promoter	4,912
		38	Payal Jilpeshbhai Doshi	Non Promoter	4,912
		39	Jilpeshkumar Bhikhabhai Doshi	Non Promoter	4,912
		40	Kanchanben Bhikhabhai Doshi	Non Promoter	4,912
		41	Sejal Rahul Parikh	Non Promoter	7,367
		42	Bhikhalal Chhotalal Doshi	Promoter Group	4,912
		43	Bijalben Sanyambhai Vora	Non Promoter	10,000
		44	Ritesh Rajnibhai Shah	Non Promoter	11,250
		45	Rajnibhai Virchandbhai Shah	Non Promoter	13,750
		46	Akshat Greentech Private Limited	Non Promoter	36,837

		47	Naresh Saraaf	Non Promoter	14,735
		48	Singularity Equity Fund I	Non Promoter	1,71,906
		49	Emerge Capital Opportunities Scheme	Non Promoter	36,837
		50	Monika Rajesh Agarwal	Non Promoter	4,912
		51	Deepak Dalmia	Non Promoter	4,371
		52	Garima Chordia	Non Promoter	4,912
		53	Sanjay Popatlal Jain	Non Promoter	5,894
		54	Kewalramani Sujay Mohanlal	Non Promoter	5,894
		55	Rahil Vipulbhai Mehta	Non Promoter	1,621
		56	Priyesh Nikeshkumar Mehta	Non Promoter	1,621
		57	Rutvi Priyesh Mehta	Non Promoter	1,670
		<b>TOTAL</b>			<b>8,73,294</b>

### Annexure- III

Disclosure pursuant to Para A of Part A of Schedule III of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 read with read with SEBI Circular No CIR/CFD/CMD/4/2015 dated September 9, 2015

Disclosure post allotment of Securities by way of preferential issue

Sr. No.	Particulars	Details																																																												
1	Outcome of the subscription	Allotment of 26,44,836 fully convertible warrants each convertible into, or exchangeable convertible into equivalent number of equity shares for an aggregate consideration of Rs. 1,34,62,21,524/- of which Rs. 33,65,55,381/- (being 25% of the aggregate consideration) has been paid up front.																																																												
2	Issue Price / allotted price (in case of convertibles)	<p>The warrants are issued at a price of Rs. 509/- each.</p> <p>An amount equivalent to 25% of the Warrant Issue Price of each warrant has been paid on subscription and allotment of each Warrant.</p> <p>The balance 75% shall be payable by the warrant holder(s), on exercise of rights attached to the warrants, within a period of 18 months from the date of allotment.</p>																																																												
3	Number of investor(s)	<p>57 (Fifty seven)</p> <table border="1"> <thead> <tr> <th>SR. No.</th> <th>NAME OF ALLOTTEE(S)</th> <th>CATEGORY (PROMOTER/NON PROMOTER)</th> <th>NO OF FULLY CONVERTIBLE WARRANTS IN THE COMPANY ALLOTTED</th> </tr> </thead> <tbody> <tr> <td>1</td> <td>Parag Chandulal Mehta</td> <td>Non Promoter</td> <td>1,03,143</td> </tr> <tr> <td>2</td> <td>Alka Rajesh Agrawal</td> <td>Non Promoter</td> <td>44,204</td> </tr> <tr> <td>3</td> <td>Kedia Seema</td> <td>Non Promoter</td> <td>7,367</td> </tr> <tr> <td>4</td> <td>Sadhna Devi Chandak</td> <td>Non Promoter</td> <td>7,367</td> </tr> <tr> <td>5</td> <td>UMESH SURENDRA KAMATH</td> <td>Non Promoter</td> <td>7,367</td> </tr> <tr> <td>6</td> <td>Meghana Divyagnan Sarvaiya</td> <td>Non Promoter</td> <td>7,367</td> </tr> <tr> <td>7</td> <td>Nirmal Kumar Deepchand Gangwal</td> <td>Non Promoter</td> <td>73,673</td> </tr> <tr> <td>8</td> <td>Piyush Goyal</td> <td>Non Promoter</td> <td>37,500</td> </tr> <tr> <td>9</td> <td>Sharda Agarwal</td> <td>Non Promoter</td> <td>22,102</td> </tr> <tr> <td>10</td> <td>Nachiket V Deo</td> <td>Non Promoter</td> <td>3,683</td> </tr> <tr> <td>11</td> <td>Neeraj Khubchandani</td> <td>Non Promoter</td> <td>3,683</td> </tr> <tr> <td>12</td> <td>Kaushik Daga</td> <td>Non Promoter</td> <td>1,47,347</td> </tr> <tr> <td>13</td> <td>Kalpita Agencies Private Limited</td> <td>Non Promoter</td> <td>44,204</td> </tr> <tr> <td>14</td> <td>Gaurav Karnawat</td> <td>Non Promoter</td> <td>73,673</td> </tr> </tbody> </table>	SR. No.	NAME OF ALLOTTEE(S)	CATEGORY (PROMOTER/NON PROMOTER)	NO OF FULLY CONVERTIBLE WARRANTS IN THE COMPANY ALLOTTED	1	Parag Chandulal Mehta	Non Promoter	1,03,143	2	Alka Rajesh Agrawal	Non Promoter	44,204	3	Kedia Seema	Non Promoter	7,367	4	Sadhna Devi Chandak	Non Promoter	7,367	5	UMESH SURENDRA KAMATH	Non Promoter	7,367	6	Meghana Divyagnan Sarvaiya	Non Promoter	7,367	7	Nirmal Kumar Deepchand Gangwal	Non Promoter	73,673	8	Piyush Goyal	Non Promoter	37,500	9	Sharda Agarwal	Non Promoter	22,102	10	Nachiket V Deo	Non Promoter	3,683	11	Neeraj Khubchandani	Non Promoter	3,683	12	Kaushik Daga	Non Promoter	1,47,347	13	Kalpita Agencies Private Limited	Non Promoter	44,204	14	Gaurav Karnawat	Non Promoter	73,673
SR. No.	NAME OF ALLOTTEE(S)	CATEGORY (PROMOTER/NON PROMOTER)	NO OF FULLY CONVERTIBLE WARRANTS IN THE COMPANY ALLOTTED																																																											
1	Parag Chandulal Mehta	Non Promoter	1,03,143																																																											
2	Alka Rajesh Agrawal	Non Promoter	44,204																																																											
3	Kedia Seema	Non Promoter	7,367																																																											
4	Sadhna Devi Chandak	Non Promoter	7,367																																																											
5	UMESH SURENDRA KAMATH	Non Promoter	7,367																																																											
6	Meghana Divyagnan Sarvaiya	Non Promoter	7,367																																																											
7	Nirmal Kumar Deepchand Gangwal	Non Promoter	73,673																																																											
8	Piyush Goyal	Non Promoter	37,500																																																											
9	Sharda Agarwal	Non Promoter	22,102																																																											
10	Nachiket V Deo	Non Promoter	3,683																																																											
11	Neeraj Khubchandani	Non Promoter	3,683																																																											
12	Kaushik Daga	Non Promoter	1,47,347																																																											
13	Kalpita Agencies Private Limited	Non Promoter	44,204																																																											
14	Gaurav Karnawat	Non Promoter	73,673																																																											

15	Neelima Karnawat	Non Promoter	73,673
16	Manan Keval Doshi	Non Promoter	29,469
17	Ramesh S Damani	Non Promoter	1,00,000
18	Gautam Pranlal Shah	Non Promoter	7,367
19	Hem Chand Jain	Non Promoter	33,153
20	Ramgopal Investment And Trading Company Private Limited	Non Promoter	73,673
21	Vikas Vijaykumar Khemani	Non Promoter	73,673
22	Sameer Manchanda	Non Promoter	75,000
23	Vijay Jain	Non Promoter	7,367
24	Karan Manoj Maheshwari	Non Promoter	14,734
25	Astralit Investments Private Limited	Non Promoter	73,673
26	Pravin Pannalal Shah HUF	Non Promoter	75,000
27	Jitendra Rasiklal Sanghavi	Non Promoter	29,469
28	Alok Saraf	Non Promoter	14,734
29	Priyanka Shwetkumar Koradiya	Non Promoter	1,08,750
30	Satya Pal Gulati	Non Promoter	14,734
31	Pankaj Prasoon HUF	Non Promoter	29,469
32	Arham Samkit Gandhi	Non Promoter	37,500
33	Megh Samkit Gandhi	Non Promoter	37,500
34	Prafull Rai	Non Promoter	29,469
35	Ashok Ramkishan Sikchi	Non Promoter	29,469
36	Gaurav Jain	Non Promoter	19,891
37	Raghav Bahl	Non Promoter	14,734
38	Payal Jilpeshbhai Doshi	Non Promoter	14,734
39	Jilpeshkumar Bhikhabhai Doshi	Non Promoter	14,734
40	Kanchanben Bhikhabhai Doshi	Non Promoter	14,734
41	Sejal Rahul Parikh	Non Promoter	22,102
42	Bhikhalal Chhotalal Doshi	Promoter Group	14,734
43	Bijalben Sanyambhai Vora	Non Promoter	30,000
44	Ritesh Rajnibhai Shah	Non Promoter	33,750
45	Rajnibhai Virchandbhai Shah	Non Promoter	41,250

		46	Akshat Greentech Private Limited	Non Promoter	1,10,510
		47	Naresh Saraaf	Non Promoter	44,204
		48	Singularity Equity Fund I	Non Promoter	5,15,716
		49	Emerge Capital Opportunities Scheme	Non Promoter	1,10,510
		50	Monika Rajesh Agarwal	Non Promoter	14,734
		51	Deepak Dalmia	Non Promoter	13,114
		52	Garima Chordia	Non Promoter	14,734
		53	Sanjay Popatlal Jain	Non Promoter	17,681
		54	Kewalramani Sujay Mohanlal	Non Promoter	17,681
		55	Rahil Vipulbhai Mehta	Non Promoter	4,862
		56	Priyesh Nikeshkumar Mehta	Non Promoter	4,862
		57	Rutvi Priyesh Mehta	Non Promoter	5,009
		<b>TOTAL</b>			<b>26,44,836</b>